
Whitehawk Therapeutics, Inc.: updates and filings
Price
$3.07
November 20, 2026Market cap $288M
What Ploutos Investor adds for Whitehawk Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Sep 10, 2026Officer or director changeForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 12, 2026Shareholder voteForm8-K
- Jun 9, 2026FilingFormEFFECT
- Jun 5, 2026Correspondence with the SECFormCORRESP
- Jun 5, 2026Letter from the SECFormUPLOAD
- May 29, 2026Shelf registration for future offeringsFormS-3
- May 21, 2026Other material eventsForm8-K
- May 18, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 14, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 13, 2026Material agreement entered, unregistered sale of shares, Regulation FD disclosureForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- Apr 28, 2026Additional annual meeting materialFormDEFA14A
- Apr 28, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Mar 12, 2026Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Sep 10, 2026 | 8-K | Officer or director change | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 12, 2026 | 8-K | Shareholder vote | Document |
| Jun 9, 2026 | EFFECT | Filing | Document |
| Jun 5, 2026 | CORRESP | Correspondence with the SEC | Document |
| Jun 5, 2026 | UPLOAD | Letter from the SEC | Document |
| May 29, 2026 | S-3 | Shelf registration for future offerings | Document |
| May 21, 2026 | 8-K | Other material events | Document |
| May 18, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 14, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 13, 2026 | 8-K | Material agreement entered, unregistered sale of shares, Regulation FD disclosure | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| Apr 28, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 28, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 12, 2026 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 1, 2008.
The full analysis
What do Whitehawk Therapeutics's filings show?
The filings are where every one of Whitehawk Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.